Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Paredes

Showing results (221-230 of 309) with videos related to

Pageof 31
Sort By:
Journal of Research in Medical Sciences : the Official Journal of Isfahan University of Medical Sciences|September 12, 2022
COVID-19-associated mucormycosis: A review of an emergent epidemic fungal infection in the era of COVID-19 pandemicVinay Chamola, Rasoul Mohammadi, Harish Nair, et al.
Frontiers in Microbiology|May 27, 2022
Performance of SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Tests for Omicron and Other Variants of ConcernDàlia Raïch-Regué, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, et al.
Infectious Diseases and Therapy|April 19, 2023
Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE StudySamuel M Brown, Morgan J Katz, Adit A Ginde, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2009
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211Athe M N Tsibris, Roger Paredes, Amy Chadburn, et al.
Journal of Infection and Public Health|December 11, 2025
HCV infection, risk factors and PrEP use among HIV-negative MSM and TW at a community health centreÀngel Rivero, Albert Dalmau-Bueno, Félix Pérez, et al.
Nutrients|April 3, 2021
Adherence to a Supplemented Mediterranean Diet Drives Changes in the Gut Microbiota of HIV-1-Infected IndividualsRoque Pastor-Ibáñez, Juan Blanco-Heredia, Florencia Etcheverry, et al.
The Lancet. Infectious Diseases|July 17, 2025
Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trialEdward Weinstein, Roger Paredes, Annie Gardner, et al.
Journal for Immunotherapy of Cancer|March 30, 2021
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)Maria Gonzalez-Cao, Teresa Puertolas, Mar Riveiro, et al.
Scientific Reports|February 2, 2020
Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testingEmma R Lee, Neil Parkin, Cheryl Jennings, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 13, 2025
Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Roger Paredes, Pedro Cahn, et al.
Pageof 31

Showing results (221-230 of 309) with videos related to

Sort By:
Pageof 31
Journal of Research in Medical Sciences : the Official Journal of Isfahan University of Medical Sciences|September 12, 2022
COVID-19-associated mucormycosis: A review of an emergent epidemic fungal infection in the era of COVID-19 pandemicVinay Chamola, Rasoul Mohammadi, Harish Nair, et al.
Frontiers in Microbiology|May 27, 2022
Performance of SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Tests for Omicron and Other Variants of ConcernDàlia Raïch-Regué, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, et al.
Infectious Diseases and Therapy|April 19, 2023
Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE StudySamuel M Brown, Morgan J Katz, Adit A Ginde, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2009
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211Athe M N Tsibris, Roger Paredes, Amy Chadburn, et al.
Journal of Infection and Public Health|December 11, 2025
HCV infection, risk factors and PrEP use among HIV-negative MSM and TW at a community health centreÀngel Rivero, Albert Dalmau-Bueno, Félix Pérez, et al.
Nutrients|April 3, 2021
Adherence to a Supplemented Mediterranean Diet Drives Changes in the Gut Microbiota of HIV-1-Infected IndividualsRoque Pastor-Ibáñez, Juan Blanco-Heredia, Florencia Etcheverry, et al.
The Lancet. Infectious Diseases|July 17, 2025
Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trialEdward Weinstein, Roger Paredes, Annie Gardner, et al.
Journal for Immunotherapy of Cancer|March 30, 2021
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)Maria Gonzalez-Cao, Teresa Puertolas, Mar Riveiro, et al.
Scientific Reports|February 2, 2020
Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testingEmma R Lee, Neil Parkin, Cheryl Jennings, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 13, 2025
Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Roger Paredes, Pedro Cahn, et al.
Pageof 31